SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+ and TMTG News. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

Recent discussions around DJT are buzzing with political undertones, touching on topics from border security and immigration to trade relations. Community sentiment appears divided, with some users expressing concerns about potential impacts on American ranchers and farmers. The stock's performance and broader implications of political events remain central to the conversation.

Solana is a highly functional open source project that banks on blockchain technology’s permissionless nature to provide decentralized finance (DeFi) solutions. It is a layer 1 network that offers fast speeds and affordable costs. While the idea and initial work on the project began in 2017, Solana was officially launched in March 2020 by the Solana Foundation with headquarters in Geneva, Switzerland.

Solana

Solana is trending, with community members discussing its price action and potential. There is chatter about exchange-traded funds (ETFs), with Fidelity recently listing Solana. Some users are highlighting Solana's ecosystem and potential for future growth.

BrokeCoin is a meme-meets-utility cryptocurrency project operating under the ethos of Transparency, Community, and Respect. Formally registered as an LLC in Wyoming, USA, BrokeCoin is building an expansive ecosystem that combines light-hearted spirit of meme culture with real-world crypto utilities—spanning gaming, staking, NFTs, web services, and an e-commerce platform. Brokecoin believes in developing useful and interesting meme-inspired utilities to both service the crypto industry, and generate value for holders.

Brokecoin

Brokecoin is trending as the community rallies around its commitment to building and developing the project, highlighting its staking on BiFinance and Broke Perspective media platform. Despite market dips, the community emphasizes its resilience, ongoing development, and the pursuit of long-term growth on the Solana blockchain. Talk centers on the potential for a resurgence in price action and a push towards a token supply burn at 2500 watchers.

Newmont Corp. engages in the exploration and acquisition of gold properties, containing copper, silver, lead, zinc or other metals. It operates through the following geographical segments: Canada, Mexico, Suriname, Argentina, Peru, Australia, Papua New Guinea, Ghana, and U.S. The company was founded by William Boyce Thompson on May 2, 1921 and is headquartered in Denver, CO.

Newmont Corp

Newmont is trending as investors digest recent earnings and production updates, with community sentiment split between disappointment in the new CEO's presentation and optimism about the company's long-term value given current gold prices. Discussions revolve around whether the recent price action represents a buying opportunity or a sign of deeper issues, with some suggesting potential manipulation to drive down call options. The broader context includes rising gold prices and speculation about potential mergers within the mining sector.

$BALLIN is the perfect meme for everyone showing up every single day.  To be BALLIN, you gotta B-All-In.  The meaning to B All In doesn't only apply to the funds you invest.  It's about dedication.   The countless hours of research.   The endless raiding and working for your bags.  Not knowing how to quit while everyone is telling you you're wrong.  It's about believing in something.  Keep $BALLIN

B All In

$BALLIN is gaining attention, with community members highlighting its availability on Phantom Wallet and touting potential gains. The conversation centers around 'bags,' 'moonshots,' and 'rocket mode,' with many suggesting it's an opportune time to get in early. Some users are expressing concerns and caution.

Nebius Group NV is a technology company that provides infrastructure and services to AI builders worldwide. It offers Nebius AI, an AI-centric cloud platform provides full-stack infrastructure, including large-scale GPU clusters, cloud services, and developer tools. The company also operates through specialized brands: Toloka AI, which partners in data for generative AI development; TripleTen, an edtech platform focused on re-skilling individuals for tech careers; and Avride, which develops autonomous driving technology. Nebius Group was founded by Elena Kolmanovskaya, Ilya Segalovich, Mikhail Fadeev, and Arkady Volozh in 1989 and is headquartered in Amsterdam, the Netherlands.

Nebius Group N.V. - Ordinary Shares - Class A

Nebius Group N.V. 

NBIS is trending due to a sharp rebound after a significant decline, with community members debating whether the bottom has been reached and discussing potential catalysts like earnings and partnerships. The stock's connection to the AI infrastructure boom and recent news regarding accelerated power hookups for data centers are also fueling interest. Bullish investors are highlighting the company's long-term potential and the increasing demand for AI infrastructure.

Lumen Technologies, Inc. is an investment holding company, which engages in the provision of integrated communications to residential and business customers. It operates through the Business and Mass Markets segments. The Business segment provides products and services under four sales channels to enterprise and commercial customers. The Mass Markets segment focuses on consumer and small business customers. The company was founded in 1930 and is headquartered in Monroe, LA.

Lumen Technologies Inc

Lumen Technologies is trending as investors discuss its potential role in AI infrastructure, particularly following a $200M deal with Palantir that has sparked optimism. Community members are focused on Lumen's fiber optic network and data center connectivity, anticipating significant growth and a possible turnaround for the company. Bullish sentiment is building, with many expressing confidence in Lumen's long-term prospects within the evolving AI landscape.

USDC is a fully collateralized US dollar stablecoin. USDC is the bridge between dollars and trading on cryptocurrency exchanges. The technology behind CENTRE makes it possible to exchange value between people, businesses and financial institutions just like email between mail services and texts between SMS providers. We believe by removing artificial economic borders, we can create a more inclusive global economy.

USD Coin

USD Coin is trending amid discussions around stablecoin regulation and increasing adoption, particularly on Solana. Community members are highlighting its use in remittances, DeFi, and as a hedge against inflation in emerging markets. The meme coin BrokeCoin is also garnering attention within the USDC conversation.

Deckers Outdoor Corp. engages in the business of designing, marketing, and distributing footwear, apparel, and accessories developed for both everyday casual lifestyle use and high performance activities. It operates through the following segments: UGG Brand, HOKA Brand, Teva Brand, Sanuk Brand, Other Brands, and Direct-to-Consumer. The UGG Brand segment offers a line of premium footwear, apparel, and accessories. The HOKA Brand segment sells footwear and apparel that offers enhanced cushioning and inherent stability with minimal weight, originally designed for ultra-runners. The Teva Brand segment focuses on the sport sandal and modern outdoor lifestyle category, such as sandals, shoes, and boots. The Sanuk Brand segment originated in Southern California surf culture and has emerged into a lifestyle brand with a presence in the relaxed casual shoe and sandal categories. The Other Brands segment includes the Koolaburra by UGG brand. The Direct-to-Consumer segment consists of retail stores and e-commerce websites. The company was founded by Douglas B. Otto in 1973 and is headquartered in Goleta, CA.

Deckers Outdoor Corp.

Deckers (DECK) is trending due to a significant after-hours selloff despite the company reporting better-than-expected earnings, with the community debating whether the dip is a buying opportunity or a sign of deeper issues. The cautious outlook and slowing international growth are raising concerns, while some investors point to the company's buyback program and potential for recovery. Discussions also include the impact of tariffs and comparisons to other companies in the apparel and footwear sector.

SSgA Active Trust - SPDR S&P 500 ETF Trust

The SPY is trending amid discussions around trade relations, particularly Trump's stance on Canada, and anticipation of upcoming CPI data which is expected to be a market-moving event. Community sentiment appears mixed, with some expressing skepticism about the market's sustained rally and potential impacts of the government shutdown. Overall, traders are closely watching for signals that could influence the Federal Reserve's next move.

statis crypto Watchlist

Bitcoin

Ethereum

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Strength Seen in Wave Life Sciences (WVE): Can Its 11.4% Jump Turn into More Strength?

Wave Life Sciences (WVE) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

3 Promising Genomics & Synthetic Biology Stocks in Spotlight in 2025 

GeneDx, Twist Bioscience and Wave Life Sciences are emerging as key players in the fast-growing genomics and synthetic biology space.

Shares of Wave Life Sciences (WVE) tumbled over 19% on Wednesday after the company announced that its WVE-006 led to RNA editing in all participants treated in a trial evaluating the therapy as a treatment for alpha-1-antitrypsin deficiency (AATD).AATD is an inherited genetic disorder that reduces the production of the AAT protein, which is crucial for protecting the lungs and liver. It is caused by a genetic mutation, and WVE-006 is designed to address the manifestations of AATD by correcting the mutation.The company <a target="_blank" rel="noopener noreferrer nofollow" href="https://ir.wavelifesciences.com/news-releases/news-release-details/wave-life-sciences-announces-positive-update-ongoing">announced</a> on Wednesday that WVE-006 resulted in RNA editing in all treated participants, with durable production of serum AAT at levels associated with a lower risk of liver and lung disease following repeat 200 mg doses.Despite the impressive first demonstration of a dynamic acute phase response post-RNA editing in alpha-1-antitrypsin deficiency, Wave Life's stock performance suggests the Street expected a greater increase in AAT protein, Leerink said. Leerink raised its price target on Wave Life Sciences to $26 from $24 and kept an ‘Outperform’ rating on the shares.Leerink further thinks investors should take advantage of this weakness to buy the stock ahead of additional important catalysts, which it remains optimistic investors will appreciate despite today's confusion.H.C. Wainwright analyst Andrew Fein, meanwhile, said Wave’s stock decline despite the “encouraging” data was an “overreaction.” The analyst stated that these results strengthen the firm's conviction that WVE-006 can deliver both lung and liver benefits, and the firm believes the current data, excluding the 400 mg multiple ascending dose data, "still shows an approval endpoint.” The analyst has a ‘Buy’ rating and $22 price target on Wave Life Sciences shares.Data from both the 200 mg and 400 mg single-dose cohorts support a monthly or less frequent subcutaneous dosing regimen, Wave Life Sciences said. Dosing is ongoing in the 400 mg multidose cohort with a monthly dosing regimen, for which Wave expects to deliver data in the first quarter of 2026. Further, all adverse events observed in the study were mild to moderate in intensity, and there were no serious adverse events or discontinuations, it added.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/WVE">WVE</a> jumped from ‘bearish’ to ‘extremely bullish’ territory over the past 24 hours while message volume rose from ‘low’ to ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:623/59;" src="https://news.stocktwits-cdn.com/Screenshot_2025_09_03_at_2_24_05_PM_png_6c95483e4e.webp" alt="WVE's Sentiment Meter and Message Volume as of 2:24 p.m. ET on Sept. 3, 2025 | Source: Stocktwits" width="623" height="59"><figcaption>WVE's Sentiment Meter and Message Volume as of 2:24 p.m. ET on Sept. 3, 2025 | Source: Stocktwits</figcaption></figure>GSK has the exclusive global license for WVE-006. Development and commercialization responsibilities will transfer to GSK after Wave completes the study. Wave is eligible for up to $525 million in milestone payments, as well as tiered royalties on net sales, for WVE-006.WVE stock is down 37% this year but up approximately 40% over the past 12 months.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/ford-reports-near-four-percent-jump-in-us-vehicle-sales-in-august/chwT6RHRd8r">Ford Reports Near 4% Jump In US Vehicle Sales In August</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Wave Life Sciences Tumbled 19% Today, But Not Everyone’s Disappointed – Find Out Why

Wave Life Sciences said Wednesday that its therapy WVE-006 successfully edited RNA in all trial participants, producing lasting levels of a key protein tied to lower risks of liver and lung disease after repeat 200 mg doses.

Equity

Wave Life Sciences (WVE) Reports Q2 Loss, Misses Revenue Estimates

Wave Life Sciences (WVE) delivered earnings and revenue surprises of -6.90% and -31.16%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Illumina (ILMN) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

Illumina (ILMN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Raymond James bullish on biotech firms on favorable valuation

Investing.com -- Raymond James started coverage on biotechnology companies, rating Avidity Biosciences and Disc Medicine at Strong Buy and assigning Outperform ratings to Dyne Therapeutics, Tectonic Therapeutic, and Wave Life Sciences (NASDAQ:WVE), pointing to a sector-wide opportunity amid “suppressed valuations.”

Geron (GERN) Reports Q1 Loss, Lags Revenue Estimates

Biotech stocks jump as Makary outlines FDA vision, RBC comments

Investing.com -- Biotech stocks climbed Monday after new FDA Commissioner Dr. Marty Makary laid out a clear and collaborative regulatory strategy that analysts say bodes well for drug developers. In his first major interview since taking office, Makary emphasized pragmatic reforms, faster drug approvals, and modernized use of real-world data across the agency.

What's Next: WAVE Life Sciences's Earnings Preview

Shares of biotech company Wave Life Sciences ($WVE) surged as much as 74% on Wednesday after it announced a breakthrough in RNA editing to treat certain lung and liver-related genetic disorders. The announcement led to a spike in retail sentiment on Stocktwits.Cambridge, Mass-based Wave claims it has the first positive proof-of-mechanism data from its ongoing “Phase 1b/2a RestorAATion-2” study that uses RNA editing of the human genome to treat certain AATD-related lung and liver diseases.Retail sentiment was ‘extremely bullish’ (97/100) following the news with accompanying message volumes at ‘extremely high’ (96/100) on Stocktwits.<figure class="image"><a href="https://stocktwits.com/symbol/WVE/"><img style="aspect-ratio:1338/384;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/Screenshot_2024_10_16_at_10_11_52_PM_e225065c8a.png" alt="Screenshot 2024-10-16 at 10.11.52 PM.png" width="1338" height="384"></a><figcaption>WVE sentiment meter as of 12:41 pm ET| Source: Stocktwits</figcaption></figure>“Achieving the first-ever therapeutic RNA editing in humans is a significant milestone for our organization, for our GSK collaboration, and for the entire oligonucleotide field. It also unlocks and derisks Wave’s RNA editing platform, in light of the continued strong clinical translation of our proprietary best-in-class chemistry, including PN, stereochemistry and our N3U AIMer modification,” Paul Bolno, president and CEO of Wave Life Sciences, said in a statement.Wave estimates there are about 200,000 people living with AATD in the U.S. and Europe who have limited treatment options including a weekly IV augmentation therapy for lung diseases. There are also no approved treatments for AATD liver diseases, prompting patients to undergo liver transplants.Stocktwits users were optimistic about the drug’s prospects.<stembedurl>https://stocktwits.com/S2023/message/589126624</stembedurl> WVE stock is up 175% year-to-date.For updates and corrections, email <a target="_blank" rel="noopener noreferrer nofollow" href="mailto:newsroom@stocktwits.com">newsroom@stocktwits.co</a>m

Wave estimates there are about 200,000 people living with AATD in the US and Europe who currently have limited treatment options.

Wave Life Sciences Stock Surges On RNA Editing Breakthrough: Retail Turns Extremely Bullish

Retail sentiment was ‘extremely bullish’ (97/100) following the news.

Wave Life Sciences Ltd. is a clinical-stage biotechnology company, which focuses on developing its proprietary RNA medicines platform and PRISM. It also develop and commercialize a pipeline RNA medicines in a variety of therapeutic areas. The company was founded by Gregory L. Verdine and Takeshi Wada on July 23, 2012 and is headquartered in Singapore.

Current Price	$7.05
Prev Close	$7.18
Open	$7.23
Dividend Yield	N/A
50-Day Moving Average	$7.97
Beta	1.36
Avg. Volume	2.45M
PE Ratio	-7.90

52-Week High	$16.74
52-Week Low	$5.28
Market Capitalization	$1.12B
EPS (Annual)	-$0.7015
Price to Book	7.88
Revenue Per Employee	$376,048.61
Enterprise Value/EBITDA	N/A

WVE
Wave Life Sciences Ltd.

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest WVE News

WVEWave Life Sciences Ltd.